Late-Breaking Abstracts Announced for the Society for Immunotherapy of Cancer's 36th Annual Meeting

MILWAUKEE, Nov. 1, 2021 /PRNewswire-PRWeb/ -- The Society for Immunotherapy of Cancer (SITC) received a record-breaking number of abstract submissions in 2021, and has announced titles and authors for late-breaking abstracts (LBA). The abstracts will be presented at SITC's upcoming 36th Annual Meeting & Pre-Conference Programs taking place November 10–14, 2021, in Washington, D.C.

"SITC is pleased to incorporate these abstracts into an already stellar schedule. The late-breaking abstracts will round out the content offered at the 36th Annual Meeting and highlight more recent data and research," said SITC President Patrick Hwu, MD.

The late-breaking abstracts are:

• (945) Characterization of the immune landscape of malignant pleural effusion composition from patients with metastatic breast carcinoma: A Pilot study

Caddie Dy Laberiano, MD – The University of Texas MD Anderson Cancer Center

• (946) Standardized transcriptional profiling for optimizing cellular therapies: A Multi-Center PICI-NanoString collaboration

Sarah E. Church, PhD – NanoString Technologies

• (947) Recombinant Myxoma Virus MC509-N1 Demonstrates Antitumor Efficacy as Monotherapy and in Combination with Immune Checkpoint Inhibitors

Enkhtaivan Gansukh, PhD – Virocure Inc.

• (948) Final results from AIPAC: A phase IIb comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- MBC

Hans Wildiers, MD – University Hospitals Leuven; Department of General Medical Oncology and Multidisciplinary Breast Centre

• (949) First-in-human study of the first acid pH-sensitive and recycling CTLA-4 antibody that preserves the immune tolerance checkpoint to avoid immunotherapy-related adverse events in cancer patients

Tianhong Li, MD, PhD – University of California at Davis

• (950) Final analysis: phase 1b study investigating intratumoral injection of Toll-like receptor 9 agonist vidutolimod ± pembrolizumab in patients with PD-1 blockade–refractory melanoma

John M. Kirkwood, MD – University of Pittsburgh Medical Center

• (951) A Phase 1 first in human study of adenovirally transduced anti-HER2 CAR Macrophages in subjects with HER2 overexpressing solid tumors: preliminary safety, pharmacokinetics, and TME reprogramming data

Kim A. Reiss, MD -- University of Pennsylvania

• (952) Phase II trial of AV-GBM-1: dendritic cell vaccine pulsed with lysate enriched for autologous tumor-initiating cell antigens in the treatment of patients with newly diagnosed glioblastoma

Daniela A. Bota, MD, PhD – University of California Irvine

• (953) Transcriptional Analysis of Leukocytes from COVID Convalescent Donors Reveals Persistent Activation of the Innate and Adaptive Immune System

Patrick Danaher, PhD – NanoString

• (954) Clinical results from a phase I dose escalation study in treatment-naïve early stage prostate cancer patients with ORCA-010, a potency enhanced oncolytic replication competent adenovirus

Wenliang Dong, PhD, MBA – ORCA Therapeutics BV

• (955) CORE1: Phase 2, Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)

James Burke, MD – CG Oncology

• (956) Retifanlimab (INCMGA00012) in patients with recurrent MSI-H or dMMR endometrial cancer: Results from the POD1UM-101 study

Ignace Vergote, MD – University Hospitals Leuven, Leuven Cancer Institute

• (957) NKTR-255+cetuximab in patients with solid tumors: Interim safety and efficacy results from the Phase 1b dose-escalation study

Mehmet Altan, MD – The University of Texas MD Anderson Cancer Center

• (958) BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors

Andreas Mackensen, MD – University Hospital Erlangen

• (959) Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses – clinical update on the ACTengine® IMA203 trial

Martin Wermke – University Hospital Dresden

• (960) Randomized multicenter study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer

Osama E. Rahma, MD – Dana-Farber Cancer Institute

• (961) Preliminary results of a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapy

Iván Márquez-Rodas, MD, PhD – Hospital Universitario Gregorio Marañón

• (962) Integrative immunomics highlight the immunomodulatory impact of neoadjuvant chemotherapy and immune-based treatments in resected non-small-cell lung cancer

Stephanie T. Schmidt, PhD – The University of Texas MD Anderson Cancer Center

The full abstracts will be available on Nov. 9 at 8 a.m. EST in the Journal for ImmunoTherapy of Cancer (JITC) supplement.

Late-Breaking Abstract Sessions with oral abstract presentations will take place on Friday, Nov. 12 from 12:10–12:40 p.m. EST and Saturday, Nov. 13 from 12–12:30 p.m. EST. Late-Breaking Abstract posters will be presented in the Poster Hall in Washington D.C. and the virtual ePoster Hall beginning Friday, Nov. 12 at 7 a.m. EST.

To learn more about the late-breaking abstracts, visit the 36th Annual Meeting & Pre-Conference Programs website.

About SITC
The Society for Immunotherapy of Cancer (SITC) is the world's leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Established in 1984, SITC, a 501(c)(3) not-for-profit organization, serves scientists, clinicians, academicians, patients, patient advocates, government representatives and industry leaders from around the world. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word cure a reality for cancer patients everywhere. To learn more, visit http://www.sitcancer.org and follow us on Twitter, LinkedIn, Facebook and YouTube.

Media Contact

Thomas Martin, Society for Immunotherapy of Cancer, (414) 271-2456, [email protected]

Twitter

SOURCE Society for Immunotherapy of Cancer

Related Links

http://www.sitcancer.org/